PMID- 20484611
OWN - NLM
STAT- MEDLINE
DCOM- 20110421
LR  - 20220409
IS  - 1552-4604 (Electronic)
IS  - 0091-2700 (Linking)
VI  - 51
IP  - 2
DP  - 2011 Feb
TI  - Database evaluation of the effects of long-term rosiglitazone treatment on 
      cardiovascular outcomes in patients with type 2 diabetes.
PG  - 173-80
LID - 10.1177/0091270010368281 [doi]
AB  - Recent meta-analyses suggest an increased risk of acute myocardial infarction 
      (AMI) in patients with type 2 diabetes mellitus (T2DM) treated with 
      rosiglitazone. These meta-analyses have drawn considerable criticisms. 
      Retrospective observational studies do not consistently support this association. 
      The objective of this study was to compare rates of adverse cardiovascular 
      outcomes in T2DM patients treated with rosiglitazone alone or combined with 
      metformin or metformin alone. This retrospective study, using the health 
      maintenance organization database, included patients who were dispensed 
      rosiglitazone (alone or with metformin) for at least 6 months as follows: 
      rosiglitazone alone (n = 745), rosiglitazone and metformin (n = 2753), and 
      metformin alone (n = 11 938). Adverse cardiovascular outcomes were new diagnosis 
      of AMI, acute coronary syndrome (ACS), coronary revascularization (CRV), 
      congestive heart failure (CHF), and all-cause mortality. Mean on-treatment 
      follow-up was 30 months. After adjustment for covariates found to be significant 
      in univariate analyses, rosiglitazone was associated only with CHF (hazard ratio 
      [HR] = 2.23; 95% confidence interval [CI]: 1.41-1.95) with no increase of risk 
      for AMI (HR = 1.13; 95%CI: 0.60-2.12), ACS (HR = 0.85; 95% CI: 0.57-1.26), 
      coronary revascularization (HR = 1.22; 95% CI:0.82-1.54), or all-cause mortality 
      (HR = 1.15; 95% CI: 0.85-1.56). In this community-based cohort, 30 months of 
      therapy with rosiglitazone treatment was associated with increased risk of CHF 
      but was not associated with increased risk of AMI, ACS, coronary 
      revascularization, or all-cause mortality.
FAU - Loebstein, Ronen
AU  - Loebstein R
AD  - Department of Pharmaceutics and Clinical Pharmacology, Maccabi Healthcare 
      Services, 27, Hamered St, Tel Aviv, Israel. loebst_r@mac.org.il
FAU - Dushinat, Marina
AU  - Dushinat M
FAU - Vesterman-Landes, Janet
AU  - Vesterman-Landes J
FAU - Silverman, Barbara
AU  - Silverman B
FAU - Friedman, Nurit
AU  - Friedman N
FAU - Katzir, Itzhak
AU  - Katzir I
FAU - Kurnik, Daniel
AU  - Kurnik D
FAU - Lomnicky, Yossef
AU  - Lomnicky Y
FAU - Kokia, Ehud
AU  - Kokia E
FAU - Halkin, Hillel
AU  - Halkin H
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20100519
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiazolidinediones)
RN  - 05V02F2KDG (Rosiglitazone)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Aged
MH  - Cardiovascular Diseases/epidemiology/etiology
MH  - Databases, Factual
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/epidemiology/etiology
MH  - Humans
MH  - Hypoglycemic Agents/*adverse effects/therapeutic use
MH  - Male
MH  - Metformin/*adverse effects/therapeutic use
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Rosiglitazone
MH  - Thiazolidinediones/*adverse effects/therapeutic use
EDAT- 2010/05/21 06:00
MHDA- 2011/04/22 06:00
CRDT- 2010/05/21 06:00
PHST- 2010/05/21 06:00 [entrez]
PHST- 2010/05/21 06:00 [pubmed]
PHST- 2011/04/22 06:00 [medline]
AID - 0091270010368281 [pii]
AID - 10.1177/0091270010368281 [doi]
PST - ppublish
SO  - J Clin Pharmacol. 2011 Feb;51(2):173-80. doi: 10.1177/0091270010368281. Epub 2010 
      May 19.